Compare GKOS & BGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GKOS | BGC |
|---|---|---|
| Founded | 1998 | 1945 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.4B |
| IPO Year | 2015 | 1999 |
| Metric | GKOS | BGC |
|---|---|---|
| Price | $107.89 | $8.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 2 |
| Target Price | ★ $122.08 | $14.50 |
| AVG Volume (30 Days) | 1.1M | ★ 2.9M |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 0.93% |
| EPS Growth | N/A | ★ 36.46 |
| EPS | N/A | ★ 0.33 |
| Revenue | $469,820,000.00 | ★ $2,640,884,000.00 |
| Revenue This Year | $30.89 | $35.74 |
| Revenue Next Year | $24.36 | $11.43 |
| P/E Ratio | ★ N/A | $25.93 |
| Revenue Growth | ★ 30.38 | 24.59 |
| 52 Week Low | $73.16 | $7.24 |
| 52 Week High | $163.71 | $10.96 |
| Indicator | GKOS | BGC |
|---|---|---|
| Relative Strength Index (RSI) | 73.56 | 45.57 |
| Support Level | $104.11 | $8.52 |
| Resistance Level | $107.18 | $8.76 |
| Average True Range (ATR) | 4.40 | 0.22 |
| MACD | 1.26 | 0.01 |
| Stochastic Oscillator | 92.97 | 50.22 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
BGC Group Inc is a brokerage and financial technology company that serves financial markets, energy, and commodities markets. Its service and product offerings include brokerage for a wide range of financial products, including fixed income, equities, commodities, derivatives, and real estate, software solutions for trading platforms, clearing, trade execution, and other back-office services. Its clients mostly include banks, financial institutions, and corporate clients. BGC operates in one reportable segment, which is providing brokerage services. Geographically, the company generates a majority of its revenue from Europe, Middle East and Africa (EMEA), followed by the Americas and the Asia-Pacific region.